Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Total revenues were $5.5M Q4 and $49.8M FY2025, net loss was $15.5M Q4 and $50.3M FY2025, and cash was $125.2M at year-end.
Key pipeline milestones: SONATA-HCM >50% enrolled, expected topline Q1 2027; NDA resubmission for T1D planned in 2026 if STENO1 data meet FDA requirements; pilavapadin cleared for Phase 3 by FDA End-of-Phase 2. In Feb 2026 Lexicon received >$100M in new cash including ~$96.7M equity proceeds and a $10M Novo Nordisk milestone.
Positive
- $45M licensing revenue from Novo Nordisk recognized in 2025
- Research and development expenses decreased to $61.1M in 2025
- Selling, general and administrative expenses decreased to $37.3M in 2025
- Received approximately $96.7M net proceeds from equity raise in Feb 2026 plus a $10M milestone
Negative
- Year-end cash, investments and restricted cash declined to $125.2M from $238.0M a year earlier
- Net loss remained $50.3M for full-year 2025 despite expense reductions
- Revenue concentration: $45M of FY2025 revenue tied to a single Novo Nordisk license milestone
News Market Reaction – LXRX
On the day this news was published, LXRX gained 0.61%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.7% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $746M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LXRX was up 1.24% pre-announcement while close peers showed mixed moves (e.g., FULC +6.1%, AURA -2.69%, INBX -1.53%, SLDB +1.66%). Momentum scanner only flagged LRMR (-2.39%). This points to stock-specific factors rather than a broad biotech rotation.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | +3.6% | Revenue jump from Novo upfront and INPEFA with pipeline progress across programs. |
| Aug 06 | Q2 2025 earnings | Positive | +9.5% | Shift to net income on higher revenues and advancing key pipeline assets. |
| May 13 | Q1 2025 earnings | Positive | -15.6% | Novo Nordisk deal and dose selection for pilavapadin alongside reduced loss. |
| Mar 06 | Q4 2024 earnings | Positive | +6.5% | Viatsris upfront revenue and positive Phase 2b pilavapadin data highlighted. |
| Nov 12 | Q3 2024 earnings | Positive | -8.4% | Viatris licensing economics and PROGRESS trial progress despite higher spend. |
Earnings updates often coincided with pipeline milestones and partnership news, with three past reports seeing positive price alignment and two selling off despite constructive updates.
Over the past five earnings cycles, Lexicon has repeatedly paired financials with meaningful pipeline and partnership progress. Prior reports highlighted upfront and potential milestone payments from Novo Nordisk, Viatris licensing economics, and advancement of sotagliflozin, pilavapadin and LX9851. Price reactions ranged from -15.57% to +9.52%, showing that even positive operational updates sometimes met selling pressure. Today’s Q4 2025 release continues themes of expense reduction, cash runway actions and late-stage trial execution across cardiometabolic and neuropathic pain programs.
Historical Comparison
Over the last five earnings releases, LXRX’s average move was -0.86%, with both strong rallies and sharp selloffs, framing this report within a history of volatile post-earnings reactions.
Earnings updates have traced a shift from heavy losses and higher spend in 2024 toward 2025’s improved net results, expanded non-dilutive funding from Novo Nordisk and Viatris, and steady advancement of sotagliflozin, pilavapadin and LX9851 into later-stage development.
Market Pulse Summary
This announcement combines Q4 and full-year 2025 results with clear execution milestones: reduced net loss, sharply lower R&D and SG&A, and added liquidity from a recent financing and Novo Nordisk milestones. Pipeline updates span sotagliflozin in HCM and T1D, pilavapadin moving toward Phase 3 in DPNP, and LX9851 under a deal potentially worth up to $1 billion. Investors may watch future earnings for cash trends, trial timelines and additional partnership or milestone developments.
Key Terms
new drug application (nda) regulatory
end-of-phase 2 regulatory
phase 3 medical
investigational new drug (ind) regulatory
hypertrophic cardiomyopathy (hcm) medical
diabetic peripheral neuropathic pain (dpnp) medical
sglt1 and sglt2 medical
placebo-controlled medical
AI-generated analysis. Not financial advice.
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM
Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions
Strengthened financial position with more than
Conference call and webcast at 8:30 am ET
THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.
“The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “We made substantial progress on all aspects of the business by advancing our pipeline programs, establishing strong development and commercialization agreements with leading global collaborators, working closely with regulators, and remaining operationally efficient. As a result, we have begun 2026 with tremendous momentum and are well-positioned to successfully execute on multiple important catalysts ahead.”
Scott Coiante, Lexicon’s senior vice president and chief financial officer, further commented, “Over the past year, we have pulled multiple levers to strengthen our financial position and extend our cash runway to support our robust clinical development pipeline. Our recent capital raise and milestone payment received from Novo Nordisk resulted in more than
Fourth Quarter 2025 Business and Pipeline Highlights
Cardiometabolic
Sotagliflozin
Sotagliflozin is an oral inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA®.
Hypertrophic Cardiomyopathy (HCM)
- Enrollment continues in SONATA-HCM, a pivotal Phase 3 placebo-controlled study with a targeted enrollment of 500 patients with obstructive or nonobstructive HCM.
- Lexicon has completed the initiation of 130 sites in 20 countries across the United States, Europe and Latin America.
- The study has surpassed 50 percent enrollment and Lexicon continues to expect enrollment completion in mid-2026, with topline results in the first quarter of 2027.
Type 1 Diabetes (T1D) (ZYNQUISTA®)
- Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population which has not benefitted from a new treatment mechanism since the discovery of insulin.
- Based on U.S. Food and Drug Administration (FDA) feedback, Lexicon remains on track for potential New Drug Application (NDA) resubmission and regulatory approval in 2026 if the patient exposure and safety data requirements identified by the FDA are achieved by STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark).
Viatris License for All Indications Ex-U.S. and Ex-Europe
- Lexicon continues to support licensee Viatris in its regulatory filing and commercial strategy for sotagliflozin outside of the U.S. and Europe and in 2025 shipped the first commercial product to the United Arab Emirates, the first country to obtain approval outside of the U.S.
- Viatris submitted applications for regulatory approval in several other markets in 2025, including Canada, Australia and New Zealand, and preparations are underway by Viatris for regulatory submissions in additional ex-U.S. and ex-European markets throughout 2026.
LX9851 for Obesity and Associated Cardiometabolic Disorders
LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by Novo Nordisk for obesity and weight management.
- All Investigational New Drug (IND) application-enabling activities were completed by Lexicon in 2025.
- In February 2026, the company received a
$10 million milestone payment from Novo Nordisk, with potential for up to$20 million in additional milestone payments in 2026. - Under the terms of Lexicon’s exclusive license agreement with Novo Nordisk, Lexicon received an upfront payment of
$45 million in April 2025 and is eligible to receive up to an aggregate of$1 billion in upfront and development, regulatory and sales milestone payments. Lexicon is also eligible for tiered royalties on net sales of LX9851.
Pain
Pilavapadin (LX9211) for Diabetic Peripheral Neuropathic Pain (DPNP)
Pilavapadin is an orally delivered, small molecule drug candidate for the treatment of DPNP, among other potential indications. Pilavapadin has the potential to be the first oral, non-opioid drug therapy approved in neuropathic pain in more than 20 years.
- Lexicon and the FDA held a successful End-of-Phase 2 meeting in the fourth quarter of 2025. The FDA raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint of the Phase 3 studies would be the change in average daily pain score (ADPS) from baseline to Week 12.
- Lexicon continues to hold partnership discussions to maximize the global potential of this investigative therapy.
Fourth Quarter 2025 Financial Highlights
Revenues: Total revenues were
Total revenues for the fourth quarter and full year 2024 include the upfront payment of
Research and Development (R&D) Expenses: Research and development expenses for the fourth quarter of 2025 decreased to
Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the fourth quarter of 2025 decreased to
Net Loss: Net loss for the fourth quarter of 2025 was
Cash, Investments, and Restricted Cash: As of December 31, 2025, Lexicon had
In February 2026, Lexicon received approximately
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 8:30 am ET / 7:30 am CT to review its financial and operating results and to provide a general business update. A live audio webcast of the call can be accessed by visiting the Events page of the Company’s investor relations website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the website for 30 days.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
| Lexicon Pharmaceuticals, Inc. | ||||||||||||||||
| Selected Financial Data | ||||||||||||||||
| Consolidated Statements of Operations Data | Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||
| (In thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Revenues: | ||||||||||||||||
| Net product revenue | $ | 1,055 | $ | 1,550 | $ | 4,647 | $ | 6,001 | ||||||||
| Licensing revenue | 4,302 | 25,000 | 45,000 | 25,000 | ||||||||||||
| Royalties and other revenue | 136 | 4 | 156 | 80 | ||||||||||||
| Total revenues | 5,493 | 26,554 | 49,803 | 31,081 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales | 201 | 348 | 274 | 616 | ||||||||||||
| Research and development, including stock-based | ||||||||||||||||
| compensation of | 11,315 | 26,685 | 61,121 | 84,480 | ||||||||||||
| Selling, general and administrative, including stock-based | ||||||||||||||||
| compensation of | 8,757 | 32,258 | 37,319 | 143,102 | ||||||||||||
| Total operating expenses | 20,273 | 59,291 | 98,714 | 228,198 | ||||||||||||
| Loss from operations | (14,780 | ) | (32,737 | ) | (48,911 | ) | (197,117 | ) | ||||||||
| Interest and other expense | (2,031 | ) | (3,858 | ) | (8,339 | ) | (15,579 | ) | ||||||||
| Interest income and other, net | 1,281 | 2,829 | 6,909 | 12,293 | ||||||||||||
| Net loss | $ | (15,530 | ) | $ | (33,766 | ) | $ | (50,341 | ) | $ | (200,403 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.04 | ) | $ | (0.09 | ) | $ | (0.14 | ) | $ | (0.63 | ) | ||||
| Weighted average common shares outstanding | ||||||||||||||||
| basic and diluted | 363,428 | 361,492 | 363,053 | 320,031 | ||||||||||||
| As of | As of | |||||||||||||||
| Consolidated Balance Sheet Data | December 31, 2025 | December 31, 2024 | ||||||||||||||
| (In thousands) | ||||||||||||||||
| Cash and investments | $ | 96,230 | $ | 237,957 | ||||||||||||
| Restricted cash | 29,000 | — | ||||||||||||||
| Property and equipment, net | 1,863 | 2,484 | ||||||||||||||
| Goodwill | 44,543 | 44,543 | ||||||||||||||
| Total assets | 184,987 | 298,420 | ||||||||||||||
| Current portion of long-term debt | 4,595 | — | ||||||||||||||
| Long-term debt, net | 49,408 | 100,298 | ||||||||||||||
| Accumulated deficit | (2,017,583 | ) | (1,967,242 | ) | ||||||||||||
| Total stockholders' equity | 107,538 | 145,950 | ||||||||||||||
FAQ
What did Lexicon (LXRX) report for revenue and net loss in Q4 2025 and full-year 2025?
What is the status and timeline for the SONATA-HCM pivotal study for sotagliflozin (LXRX)?
Is Lexicon (LXRX) planning an NDA resubmission for sotagliflozin in Type 1 diabetes in 2026?
What did the FDA End-of-Phase 2 meeting mean for pilavapadin (LXRX) development?
How did Lexicon (LXRX) strengthen its cash position in February 2026 and what cash balance did it report at year-end?
